Indenza — Enzalutamide 40 mg
Indenza is an advanced androgen receptor inhibitor for prostate cancer treatment. Active ingredient: Enzalutamide (40 mg).
Manufacturer: Aprazer Healthcare (India). It is a high-quality generic equivalent of Xtandi.
Mechanism:
Indenza acts on three different steps in the androgen receptor signaling pathway. Unlike older anti-androgens, it creates a complete blockade, preventing cancer cells from using testosterone to grow.
✅ Patient Benefit: Offers a convenient oral therapy without the need for concurrent steroid (prednisone) use, reducing steroid-related toxicity.
Treatment of metastatic castration-resistant prostate cancer (mCRPC).
Approved for use in:
- Chemo-naive setting: Patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.
- Post-docetaxel setting: Patients whose disease has progressed during or after chemotherapy.
Recommended Dose: 160 mg orally once daily.
⚠️ Pill Count:
- Each capsule contains 40 mg.
- You must take 4 capsules at the same time to reach the 160 mg dose.
Administration: Can be taken with or without food. Swallow capsules whole with water. Do not chew, dissolve, or open them.
- Seizure History: Use with caution in patients with a history of seizures, underlying brain injury, stroke, or brain tumors.
- Hypersensitivity to Enzalutamide.
- Women who are or may become pregnant (Teratogenic risk).
The most common adverse reaction is fatigue (asthenia).
Other potential side effects:
- Hot flashes.
- Headache.
- Hypertension (High blood pressure).
- Falls and Fractures (due to dizziness or weakness).
Seizure Warning: Permanently discontinue Indenza in patients who develop a seizure during treatment.
Similar products
What Customers Say
No reviews yet
Your review can be the first!